ARFORMOTEROL TARTRATE Drug Patent Profile
✉ Email this page to a colleague
When do Arformoterol Tartrate patents expire, and when can generic versions of Arformoterol Tartrate launch?
Arformoterol Tartrate is a drug marketed by Alembic, Cipla, Glenmark Pharms Ltd, Lupin, Mankind Pharma, Ritedose Corp, Slate Run Pharma, Slayback Pharma Llc, Sun Pharm, and Teva Pharms Usa. and is included in ten NDAs.
The generic ingredient in ARFORMOTEROL TARTRATE is arformoterol tartrate. There are four drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the arformoterol tartrate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Arformoterol Tartrate
A generic version of ARFORMOTEROL TARTRATE was approved as arformoterol tartrate by CIPLA on June 22nd, 2021.
Summary for ARFORMOTEROL TARTRATE
US Patents: | 0 |
Applicants: | 10 |
NDAs: | 10 |
Finished Product Suppliers / Packagers: | 9 |
Raw Ingredient (Bulk) Api Vendors: | 43 |
Clinical Trials: | 9 |
Patent Applications: | 137 |
Drug Prices: | Drug price information for ARFORMOTEROL TARTRATE |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ARFORMOTEROL TARTRATE |
What excipients (inactive ingredients) are in ARFORMOTEROL TARTRATE? | ARFORMOTEROL TARTRATE excipients list |
DailyMed Link: | ARFORMOTEROL TARTRATE at DailyMed |
Recent Clinical Trials for ARFORMOTEROL TARTRATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of California, Los Angeles | Phase 4 |
Dartmouth-Hitchcock Medical Center | Phase 4 |
Sunovion | Phase 2 |
Pharmacology for ARFORMOTEROL TARTRATE
Drug Class | beta2-Adrenergic Agonist |
Mechanism of Action | Adrenergic beta2-Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for ARFORMOTEROL TARTRATE
Paragraph IV (Patent) Challenges for ARFORMOTEROL TARTRATE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
BROVANA | Inhalation Solution | arformoterol tartrate | Eq. 0.015 mg base/ 2 mL | 021912 | 1 | 2009-10-01 |
US Patents and Regulatory Information for ARFORMOTEROL TARTRATE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Alembic | ARFORMOTEROL TARTRATE | arformoterol tartrate | SOLUTION;INHALATION | 214779-001 | May 10, 2022 | AN | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Slate Run Pharma | ARFORMOTEROL TARTRATE | arformoterol tartrate | SOLUTION;INHALATION | 213762-001 | Jun 22, 2021 | AN | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Lupin | ARFORMOTEROL TARTRATE | arformoterol tartrate | SOLUTION;INHALATION | 213068-001 | Feb 7, 2022 | AN | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Slayback Pharma Llc | ARFORMOTEROL TARTRATE | arformoterol tartrate | SOLUTION;INHALATION | 216815-001 | Nov 25, 2022 | AN | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Cipla | ARFORMOTEROL TARTRATE | arformoterol tartrate | SOLUTION;INHALATION | 207306-001 | Jun 22, 2021 | AN | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |